Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.
Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jie He(First Affiliated Hospital of Jinan University), Ziran Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Yun Ling(Zhejiang Chinese Medical University), Kai Su(Chinese Academy of Medical Sciences & Peking Union Medical College), Fengwei Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Li(Shanghai Polytechnic University), Fan Zhang(University of Vermont), Zhijie Wang(Hubei University of Medicine), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Tang, Ning Wu(Regeneron (United States)), Liang Zhao(Linyi City Chinese Medicine Hospital), Shuhang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianming Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Shun‐Yu Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Lv(Liaoning Normal University)
Cited by 5
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Cancer incidence and mortality in China, 2022
|Journal of the National Cancer Center|2024|2k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k